Published 2021 | Version v1
Publication

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

Description

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.

Additional details

Identifiers

URL
http://hdl.handle.net/11567/1036870
URN
urn:oai:iris.unige.it:11567/1036870

Origin repository

Origin repository
UNIGE